Perspective · 20 Dec 2024
Conference abstractPublished 2017
Metformin prevents cisplatin resistance by suppressing RAD51 expression in triple-negative breast cancer cells
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Triple-negative breast cancer (TNBC) is characterized by tumors that do not express the estrogen receptor (ER), progesterone receptor (PR), or HER2 genes. Since TNBC does not respond to endocrine therapy, this type of cancer presents an important clinical challenge. Although cisplatin is effective against TNBC, its use is limited due to the development of drug resistance. We found that metformin suppressed cisplatin resistance by down-regulating RAD51, a DNA homologous recombinase. Metformin suppressed cisplatin-mediated RAD51 up-regulation via regulating the protein stability and ubiquitination of RAD51. In addition, cisplatin increased phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2). Inhibition of ERK1/2 blocked cisplatin-mediated expression of RAD51. Metformin suppressed cisplatin-mediated ERK phosphorylation, indicating that metformin regulates RAD51 by suppressing cisplatin-mediated ERK activation. Moreover, metformin increased cisplatin-induced phosphorylation of Ã?³-H2AX, a hallmark of DNA double-stranded breaks, suggesting that metformin enhances sensitivity to cisplatin by inducing DNA double-stranded breaks. Overexpression of RAD51 blocked the inhibition of metformin-mediated cell invasiveness, while RAD51 knockdown enhanced cisplatin-induced invasion and migration of breast cancer cells. Collectively, these results suggest that metformin prevents cisplatin resistance by regulating RAD51 expression. PDF HTML
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Archives in Cancer Research.
Perspective · 20 Dec 2024
Chemotherapy: A Vital Treatment in the Battle Against Cancer
Perspective · 20 Dec 2024
Tumor Microenvironment: A Key Determinant of Cancer Progression
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives in Cancer Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Hyeon Soo Kim”
